Guangzhou University of Chinese Medicine, Guangzhou, China.
Department of Orthopedics, Linyi People's Hospital, Linyi, China.
Medicine (Baltimore). 2023 Dec 15;102(50):e36202. doi: 10.1097/MD.0000000000036202.
There are no serum biomarkers available in nontraumatic osteonecrosis of the femoral head in clinical practice. This study aimed to evaluate the clinical value of serum glutathione peroxidase 4 in nontraumatic osteonecrosis of the femoral head. This retrospective study analyzed serum glutathione peroxidase 4 levels and clinical data of 80 patients with nontraumatic osteonecrosis of the femoral head and 80 healthy controls between August 2021 and May 2022. Serum glutathione peroxidase 4 levels were analyzed using an enzyme-linked immunosorbent assay. The Association Research Circulation Osseous classification system determined disease progression. Clinical severity was assessed by Harris hip score and visual analogue scale. Correlations between serum glutathione peroxidase 4 and disease progression as well as clinical severity were evaluated statistically. The diagnostic accuracy of serum glutathione peroxidase 4 in nontraumatic osteonecrosis of the femoral head was determined using receiver operating characteristic analysis. The baseline characteristics of participants between 2 groups were comparable. Patients with nontraumatic osteonecrosis of the femoral head displayed a decreased glutathione peroxidase 4 level compared with healthy controls (11.87 ± 2.76 μU/mL vs 16.54 ± 4.89 μU/mL, P < .01). The levels of glutathione peroxidase 4 were inversely correlated with Association Research Circulation Osseous stage (P < .01) and visual analogue scale scores (P < .01), and positively correlated with Harris score (P < .01). Receiver operating characteristic analyses showed that area under curves of glutathione peroxidase 4 was 0.808 (95% CI 0.721-0.858) and 0.847 (95% CI 0.743-0.951) with regard to diagnosis and collapse prediction in nontraumatic osteonecrosis of the femoral head, respectively. Serum glutathione peroxidase 4 could serve as a novel biomarker for diagnosing nontraumatic osteonecrosis of the femoral head and predicting collapse of the femoral head.
在非创伤性股骨头坏死的临床实践中,尚无血清生物标志物可用。本研究旨在评估血清谷胱甘肽过氧化物酶 4 在非创伤性股骨头坏死中的临床价值。本回顾性研究分析了 2021 年 8 月至 2022 年 5 月期间 80 例非创伤性股骨头坏死患者和 80 例健康对照者的血清谷胱甘肽过氧化物酶 4 水平和临床资料。采用酶联免疫吸附试验分析血清谷胱甘肽过氧化物酶 4 水平。关联研究循环骨骼分类系统确定疾病进展。Harris 髋关节评分和视觉模拟评分评估临床严重程度。统计评估血清谷胱甘肽过氧化物酶 4 与疾病进展和临床严重程度之间的相关性。采用受试者工作特征分析确定血清谷胱甘肽过氧化物酶 4 对非创伤性股骨头坏死的诊断准确性。两组参与者的基线特征具有可比性。与健康对照组相比,非创伤性股骨头坏死患者的谷胱甘肽过氧化物酶 4 水平降低(11.87±2.76 μU/mL 比 16.54±4.89 μU/mL,P<0.01)。谷胱甘肽过氧化物酶 4 水平与关联研究循环骨骼分期呈负相关(P<0.01)和视觉模拟评分呈负相关(P<0.01),与 Harris 评分呈正相关(P<0.01)。受试者工作特征分析显示,谷胱甘肽过氧化物酶 4 的曲线下面积分别为 0.808(95%CI 0.721-0.858)和 0.847(95%CI 0.743-0.951),用于诊断和预测非创伤性股骨头坏死的股骨头塌陷。血清谷胱甘肽过氧化物酶 4 可作为诊断非创伤性股骨头坏死和预测股骨头塌陷的新型生物标志物。